Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Aura Biosciences, Inc.

AURANASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 13, 2026Accepted Nov 13, 2026, 4:03 PM ESTFiling CIK 1569064Accession 0000919574-26-007763
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Aura Biosciences, Inc.
Company CIK
0001501796
Street
80 Guest Street
City
Boston
State / country code
MA
Postal code
02135

Statement details

Amendment number
2
Security class
Common Stock, par value $0.00001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(c)

Reporting person 1

Name
Montanova Capital, LLC
Citizenship / organization
DE
Reporting person type
IA · OO
Group designation
b
Aggregate amount owned
2,973,971.00
Percent of class
2.9
Sole voting power
0.00
Shared voting power
2,973,971.00
Sole dispositive power
0.00
Shared dispositive power
2,973,971.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Averill Master Fund, Ltd.
Citizenship / organization
E9
Reporting person type
CO
Group designation
b
Aggregate amount owned
2,535,780.00
Percent of class
2.4
Sole voting power
0.00
Shared voting power
2,535,780.00
Sole dispositive power
0.00
Shared dispositive power
2,535,780.00
Aggregate excludes certain shares
N

Reporting person 3

Name
Aaron Cowen
Citizenship / organization
X1
Reporting person type
HC · IN
Group designation
b
Aggregate amount owned
2,973,971.00
Percent of class
2.9
Sole voting power
0.00
Shared voting power
2,973,971.00
Sole dispositive power
0.00
Shared dispositive power
2,973,971.00
Aggregate excludes certain shares
N

Item 1

Issuer

Aura Biosciences, Inc.

Principal executive office address

80 Guest Street, Boston, MA 02135

Item 2

Citizenship

Montanova Capital, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States

Filing person

Items 6 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by Averill Master Fund, Ltd. (the "Fund"), which may be deemed to be indirectly beneficially owned by Montanova Capital, LLC and Aaron Cowen, as well as Common Stock that may be acquired upon the exercise of pre-funded warrants with no expiration date with an exercise price of $0.00001 per share of Common Stock ("Pre-Funded Warrants"), subject to the limitations on exercise described below. The Pre-Funded Warrants are only exercisable to the extent that after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the outstanding Common Stock (the "Maximum Percentage"). By written notice to the Issuer, the Fund may from time to time increase or decrease the Maximum Percentage applicable to it to any other percentage not in excess of 19.99%, provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer. As a result of this restriction, the Pre-Funded Warrants are not all presently exercisable and the number of shares of Common Stock that may be issued upon exercise of the Pre-Funded Warrants by the above holders may change depending upon changes in the outstanding Common Stock. Montanova Capital, LLC Averill Master Fund, Ltd. Aaron Cowen

Principal business or residence address

Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America

Item 3

Not applicable indication

Y

Item 4

Percent of class

Montanova Capital, LLC - 2.9% Averill Master Fund, Ltd. - 2.4% Aaron Cowen - 2.9%

Amount beneficially owned

Montanova Capital, LLC - 2,973,971 Averill Master Fund, Ltd. - 2,535,780 Aaron Cowen - 2,973,971

Sole voting power

Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

Shared voting power

Montanova Capital, LLC - 2,973,971 Averill Master Fund, Ltd. - 2,535,780 Aaron Cowen - 2,973,971

Sole dispositive power

Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

Shared dispositive power

Montanova Capital, LLC - 2,973,971 Averill Master Fund, Ltd. - 2,535,780 Aaron Cowen - 2,973,971

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Montanova Capital, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, par value $0.00001 per share.

Item 7

Not applicable indication

N

Subsidiaries

Please see Exhibit B attached hereto.

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification

Signature comments

* Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.

Signature 1

Reporting person
Montanova Capital, LLC
Signed
/s/ Andrew Nathanson
Title
Andrew Nathanson, General Counsel and Chief Compliance Officer
Date
11/13/2026

Signature 2

Reporting person
Averill Master Fund, Ltd.
Signed
/s/ Andrew Nathanson
Title
Andrew Nathanson, Authorized Signatory
Date
11/13/2026

Signature 3

Reporting person
Aaron Cowen
Signed
/s/ Aaron Cowen
Title
Aaron Cowen
Date
11/13/2026

Filed exhibits

Company context

Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class front-line vision-preserving therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.

Current securities

Recent company filings

  1. 10-Q filingNov 9, 2026
  2. Results of Operations and Financial Condition · Other EventsNov 9, 2026
  3. SCHEDULE 13G - filed by BlackRock, Inc. regarding Aura Biosciences, Inc.Oct 27, 2026
  4. 4 filingSep 1, 2026
  5. 4 filingSep 1, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.